The initial public offering (IPO) of DAM Capital Advisors, which concluded on December 23, has garnered strong interest among retail and institutional investors. The Rs 840.25 crore offering, structured entirely as an offer for sale (OFS) of 2.

Unlisted shares of Senores Pharmaceuticals were trading at Rs 631 per share, reflecting a GMP of Rs 240 per share or 61.38 per cent over the upper end of the IPO price band of Rs 391

After finalising the share allotment status, the company will initiate refunds and transfer of shares to the demat accounts on Friday, December 27.

Investors can check their allotment through the websites of Kfin Technologies Limited and the Bombay Stock Exchange (BSE).

Bidding for the initial public offering (IPO) of Senores Pharmaceuticals Limited began on 20 December 2024 and will remain open until 24 December 2024. So, investors have just one day to apply for the Senores Pharmaceuticals IPO as bidding for the public issue ends today at 5:00 PM.

Senores Pharmaceuticals IPO receives robust response, priced at ₹372-391, with proceeds for subsidiary investment, manufacturing, and working capital.

The IPO comprises a fresh issue of shares worth Rs 500 crore and an offer-for-sale (OFS) of up to 21,00,000 equity shares by promoters and existing shareholders.

Analysts have recommended investors subscribe to the issue, citing attractive valuations and strong demand for pharmaceuticals. At the upper price band, the company is valued at a P/E ratio of 55x, with a market capitalization of Rs 1,

Senores Pharmaceuticals' initial public offering garnered 13.88 times subscription on Monday, the day two of bidding.

A mid the ongoing flurry of IPOs, three issues- Ventive Hospitality, Senores Pharmaceuticals and Carraro India- which opened for bidding on Friday, December 20, are eyeing to cumu